Co-mutation of ASXL1 and SF3B1 Predicts Poorer Overall Survival Than Isolated ASXL1 or SF3B1 Mutations
In Vivo · 2023
DOI: 10.21873/invivo.13172 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2023. Verfasst von Jinming Song und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, Moffitt Cancer Center, Tampa, FL, U.S.A.; Jinming.Song@moffitt.org. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Myeloproliferative Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematopathology, Moffitt Cancer Center, Tampa, FL, U.S.A.; Jinming.Song@moffitt.org.
- Department of Hematopathology, Moffitt Cancer Center, Tampa, FL, U.S.A.
- Berkey Preparatory School of Tampa, Tampa, FL, U.S.A.
Zitieren
APA
Song, J., Moscinski, L., Yang, E., Shao, H., Hussaini, M., & Zhang, H. (2023). Co-mutation of ASXL1 and SF3B1 Predicts Poorer Overall Survival Than Isolated ASXL1 or SF3B1 Mutations. In Vivo. https://doi.org/10.21873/invivo.13172
Vancouver
Song J, Moscinski L, Yang E, Shao H, Hussaini M, Zhang H. Co-mutation of ASXL1 and SF3B1 Predicts Poorer Overall Survival Than Isolated ASXL1 or SF3B1 Mutations. In Vivo. 2023. doi:10.21873/invivo.13172
BibTeX
@article{Song2023,
author = {Song, Jinming and Moscinski, Lynn and Yang, Ethan and Shao, Haipeng and Hussaini, Mohammad and Zhang, Hailing},
title = {Co-mutation of ASXL1 and SF3B1 Predicts Poorer Overall Survival Than Isolated ASXL1 or SF3B1 Mutations},
journal = {In Vivo},
year = {2023},
doi = {10.21873/invivo.13172}
}
EUVIMED